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Clinical outcomeAbstract Background: Prevalence of aortic valve sclerosis (AVS) increases with age. AVS is
associated with adverse cardiovascular events. The present study aimed to evaluate the association
between AVS and adverse events in patients undergoing elective percutaneous coronary intervention
(PCI) using bare metal stents (BMS).
Methods: The study included 200 consecutive patients who underwent elective (PCI) using BMS.
Echocardiographic study was done for evaluation of the presence or absence of AVS. Patients
were followed for 6 months. Major adverse cardiovascular events were deﬁned as cardiac death,
acute myocardial infarction (AMI), and stent thrombosis and target lesion revascularization. Total
MACE was deﬁned as in hospital and 6-month follow-up MACE.
Results: Of the 200 patients included in the study, 58 patients (29%) were found to have AVS. The
presence of AVS was associated with a higher prevalence of cardiovascular risk factors. The total
MACE rate was signiﬁcantly higher in patients with AVS than those with no AVS (44.8% vs.
24.6%, P= 0.0082). Using multivariable logistic regression analysis for adjustment of the baseline
and echocardiographic characteristics, the association between AVS and adverse events remained
signiﬁcant (odd ratio = 0.30; 95% conﬁdence interval, 0.11–0.826).
Conclusion: AVS is associated with increased morbidity and mortality in patients undergoing
elective PCI using BMS.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Aortic sclerosis is characterized by focal thickening and calci-
ﬁcation of a tricuspid aortic valve noted on echocardiography.It differs from aortic stenosis by the absence of ﬂow obstruc-
tion with leaﬂet excursion is not restricted and antegrade
velocity across the aortic valve is 62.5 m/s.1,2
The prevalence of aortic sclerosis increases with age,
affecting 21–26 percent of adults over the age of 65 and 40%
of those over the age of 75.3,4
Aortic sclerosis is associated with increased cardiovascular
morbidity and mortality. In the cardiovascular health study
with 5621 men and women 65 years of age or older who were
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with 50% increase in the risk of cardiovascular death and
the risk of myocardial infarction.5
In the Losartan Intervention For Endpoint Reduction In
Hypertension Study (LIFE), aortic sclerosis was associated
with increased cardiovascular events (cardiovascular death,
stroke, and myocardial infarction).6
Several mechanisms have been suggested to explain the
association between aortic sclerosis and adverse cardiovascular
outcome. Potential mechanisms include progression to hemo-
dynamically signiﬁcant aortic stenosis, subclinical atheroscle-
rosis, systemic inﬂammation and endothelial dysfunction.2
The aim of the present study was to determine the associa-
tion between the presence of aortic valve sclerosis and major
adverse cardiovascular events (MACE) in patients undergoing
elective percutaneous coronary intervention (PCI) using bare
metal stents (BMS).2. Methods
2.1. Study population
The study was conducted prospectively on 200 consecutive
patients who underwent elective PCI at interventional cathe-
terization laboratory in the cardiology department, Tanta Uni-
versity between January 2012 and June 2013.
The exclusion criteria were patients with rheumatic heart
disease, bicuspid aortic valve and patients with signiﬁcant aor-
tic stenosis (velocity across aortic valve P2.5 m/s).
2.2. Angiographic procedure
Coronary angiography and percutaneous coronary interven-
tion were done through the femoral approach. All patients
received the following regimen: (1) Clopidogrel 300–600 mg
loading dose orally followed by maintenance dose of
75 mg/day. (2) Aspirin 300 mg followed by 81–325 mg/day.
(3) During the procedure patients received unfractionated
heparin (100 IU/kg), the dose was reduced to 70 IU/kg in
case of administration of glycoprotein IIb/IIIa inhibitor
(eptiﬁbatide or tiroﬁban). (4) All patients received FDA
approved BMS.
2.3. Echocardiographic evaluation
All patients underwent a two dimensional transthoracic echo-
cardiographic and Doppler study in the left parasternal decu-
bitus position using the commercially available GE Vivid 7
echocardiograph with 2.5 MHz transducer. Echocardiographic
evaluations were conducted according to the recommendation
of the American Society of Echocardiography.7 Ejection frac-
tion (using the biplane method of disks),7 aortic transvalvular
peak velocity, aortic valve sclerosis, mitral annular calciﬁca-
tion(MAC) were speciﬁcally assessed.
Aortic valve sclerosis was deﬁned as focal areas of increased
echogenicity and thickening of the aortic valve without evi-
dence of outﬂow tract obstruction evidenced by antegrade
velocity <2.5 m/s.5
MAC was deﬁned as the presence of bright echoes at the
base of the mitral leaﬂets.82.4. Clinical deﬁnition and follow up
Clinical follow up was conducted by telephone contact or
ofﬁce visit through the follow up period.
Major adverse cardiac events (MACE), were deﬁned as car-
diac death, acute myocardial infarction (AMI), stent thrombo-
sis and target lesion revascularization. Total MACE was
deﬁned as in hospital and 6-month follow-up MACE.
The diagnosis of AMI was based on the presence of chest
discomfort or other ischemic symptoms, increased cardiac bio-
markers (creatine kinase [CK]-MB, troponin-I or troponin-T)
and 12-lead electrocardiographic ﬁndings. Among these
patients those who develop ST elevation in two contiguous
leads are designated as having ‘ST elevation MI’ STEMI while
those without ST elevation are diagnosed as having ‘non-ST
elevation MI’ NSTEMI.9
Target lesion revascularization (TLR) is deﬁned as any
repeat revascularization procedure (percutaneous or surgical)
of the original target lesion site, which includes the stented plus
edge (typically 5 mm proximal and distal to the stent)
segments.10
The Academic Research Consortium deﬁnition was used to
diagnose and grade stent thrombosis.11
3. Results
The present study included 200 patients who underwent elec-
tive PCI using (BMS).
Patients were divided into two groups according to the
presence or absence of aortic sclerosis. The ‘‘AVS’’ group
included 58 (29%) patients with aortic valve sclerosis and
‘‘No AVS’’ group included 142 (71%) patients without aortic
valve sclerosis.
3.1. Base-line and echocardiographic characteristics Table 1
Base-line and echocardiographic characteristics are shown in
Table 1. Patients in the AVS group were signiﬁcantly older,
the prevalence of hypertension, dyslipidemia, and mitral annu-
lar calciﬁcation (MAC) was higher in the AVS group also the
trans-aortic peak velocity was signiﬁcantly higher in the AVS
group (P< 0.001 for all).
There were no signiﬁcant differences between both groups
with respect to sex, prevalence of diabetes mellitus, smoking
status, family history of premature coronary artery disease,
history of prior PCI, history of prior coronary artery bypass
grafting (CABG), serum creatinine level and ejection fraction.
3.2. Angiographic and procedural characteristics Table 2
There were no signiﬁcant differences between both groups
regarding number of diseased vessels, number of treated vessel,
number of stents used, total stented length, stent diameter and
use of glycoprotein IIb/IIIa inhibitors.
3.3. Clinical outcome Table 3
3.3.1. In hospital MACE
In the AVS group, one patient (1.7%) had non-STEMI during
treatment of long calciﬁc right coronary lesion, after balloon
Table 1 Baseline and echocardiographic characteristics.
AVS (N= 58, 29%) No AVS (N= 142, 71%) P value
N % N %
Age (year) 60.66 ± 6.83 years 48.90 ± 7.02 years <0.001
Male 33 56.9 85 59.9 0.70
Hypertension 35 60.3 54 38.0 <0.001
Dyslipidemia 37 63.8 50 35.5 <0.001
Diabetes mellitus 12 20.7 22 15.5 0.37
Smoker 13 22.4 35 24.8 0.72
Family history of premature CAD 8 13.8 24 16.9 0.59
Prior PCI 11 18.9 18 12.7 0.25
Prior CABG 4 6.9 5 3.5 0.31
Creatinine 1.32 ± 0.45 1.18 ± 0.42 0.056
EF% 60.29 ± 9.27 59.63 ± 8.88 0.635
Trans-aortic peak velocity 1.40 ± 0.46 1.05 ± 0.28 <0.001
MAC 14 24.1 7 4.9 <0.001
AVS = aortic valve sclerosis, PCI = percutaneous coronary intervention, CABG= coronary artery bypass grafting, EF = ejection fraction,
MAC=mitral annular calciﬁcation, CAD= coronary artery disease.
Table 2 Angiographic characteristics of both groups.
AVS (N= 58, 29%) No AVS (N= 142, 71%) P value
N % N %
Number of diseased vessels 1 18 31.0 52 36.6 0.255
2 19 32.8 55 38.7
3 21 36.2 35 24.7
Number of treated vessels 1 29 50.0 60 42.3 0.594
2 21 36.2 61 42.9
3 8 13.8 21 14.8
Number of stents 1 19 32.8 42 29.6 0.605
2 30 51.7 69 48.6
3 8 13.8 30 21.1
4 1 1.7 1 0.7
Total stented length 34.26 ± 10.23 37.95 ± 13.03 0.055
Stent diameter 3.180 ± 0.433 3.182 ± 0.415 0.975
G IIb/IIIa inhibitors 6 10.3 12 8.5 0.671
AVS = aortic valve sclerosis.
G IIb/IIIa inhibitors = glycoprotein IIb/IIIa inhibitors.
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with TIMI2 ﬂow.
3.3.2. Six month follow-up
In the AVS group, ﬁve patients had non-STEMI (8.6%), con-
trol angiography showed in-stent restenosis in three patients
while in the other two patients there was disease progression
in previously non-signiﬁcant coronary lesions with preserva-
tion of the results of the previously deployed stents. One
patient (1.7%) had STEMI three months after the index proce-
dure because of late stent thrombosis. Nineteen patients
(32.7%) had exercise induced angina, control angiography
showing in-stent restenosis in all of them. So, in the AVS
group 23 patients (39.6%) required TLR. As in the AVS group
one patient had in hospital MACE, the total MACE rate was
44.8% (26 patients).
In the No AVS group two patients (1.4%) died suddenly,
six patients had non-STEMI (4.2%) control angiography
showed in-stent restenosis in all of them, two patients hadSTEMI (1.4%), with one patient having late stent thrombosis
5 months after the index procedure and in the other patient the
culprit lesion was in a previously non-stented vessel, 25
(17.6%) patients had exercise induced angina, control angiog-
raphy showing in-stent restenosis in all of them. So, in the no
AVS group 32 (22.5%) patients required TLR. So, the total
MACE rate was 24.6% (35 patients).
Multivariable logistic regression analysis to assess factors
predicting MACE included aortic valve sclerosis, age, sex,
hypertension, dyslipidemia, MAC and trans-aortic peak
velocity. The results showed that AVS was the only factor that
predicted MACE (odd ratio = 0.30; 95% conﬁdence interval,
0.11–0.83) (Table 4).
4. Discussion
In the present study of 200 patients undergoing elective PCI
using BMS, 58 patients (29%) were found to have AVS and
the remaining 142 patients (71%) had no AVS. Patients with
Table 3 Clinical outcome of both groups.
AVS (N= 58, 29%) No AVS (N= 142, 71%) P value
NO % NO %
In hospital MACE
Death 0 0 0 0 –
Non-fatal MI 1 1.7% 0 0
-STEMI 0 0 0 0 –
-NON-STEMI 1 1.7% 0 0
TLR 0 0 0 0
-PCI 0 0 0 0 –
-CABG 0 0 0 0
6-Month follow-up
Death 0 2 1.4% 1.00
Non-fatal MI 6 10.3% 8 5.6% 0.236
-STEMI 1 1.7% 2 1.4%
-NON-STEMI 5 8.6% 6 4.2%
TLR
-PCI 23 39.6% 32 0 22.5% 0.022
-CABG 0 0 0
Total MACE 26 44.8% 35 24.6% 0.0082
AVS = aortic valve sclerosis, MI = myocardial infarction, STEMI = ST elevation myocardial infarction, NON-STEMI = non-ST elevation
myocardial infarction, TLR= target lesion revascularization, PCI = percutaneous coronary intervention, CABG= coronary artery bypass
grafting, MACE=major adverse cardiovascular events.
126 M. Naseem, S. SamirAVS were signiﬁcantly older, with signiﬁcantly higher preva-
lence of hypertension, dyslipidemia, and MAC, the trans-aor-
tic peak velocity was also signiﬁcantly higher in the AVS
group.
Regarding the clinical outcome in the present study,
patients with AVS had a total MACE rate of 44.8% (26
patients) which was signiﬁcantly higher than the total MACE
rate of patients with no AVS which was 24.6% (35 patients).
Multivariate logistic regression analysis showed that the
increased rate of total MACE was independent of age, sex,
hypertension, dyslipidemia, MAC and the trans-aortic peak
velocity.
The observations of the present study have shown that aor-
tic valve sclerosis has a prognostic signiﬁcance in patients with
coronary artery disease undergoing elective PCI.
Theses ﬁndings are concordant with and extend the results
of previous studies showing that aortic valve sclerosis is asso-
ciated with increased cardiovascular risk.5,6,12
In the MESA (Multi-Ethnic Study of Atherosclerosis)
cohort of 6685 participants aged 45–84 years with free clinicalTable 4 Predictors of coronary artery disease according to
multivariate logistic regression analysis.
Variable Odd 95.0% C.I. for odd P-value
Lower Upper
AVS 0.30 0.11 0.83 0.020
Hypertension 0.85 0.44 1.64 0.631
Dyslipidemia 1.26 0.65 2.41 0.495
MAC 1.58 0.59 4.20 0.361
Age 0.98 0.94 1.03 0.401
Sex 1.40 0.74 2.67 0.303
Trans-aortic peak velocity 0.66 0.27 1.65 0.378
AVS = aortic valve sclerosis, MAC=mitral annular calciﬁcation.cardiovascular disease, aortic valve calcium was an indepen-
dent predictor of cardiovascular and coronary events.13
In the LIFE Echo substudy, 960 hypertensive patients with
electrocardiographic evidence of left ventricular hypertrophy,
AVS predicted the composite end point of cardiovascular
death, non-fatal stroke or non fatal myocardial infarction.14
In symptomatic patients with established cardiovascular
diseases, aortic valve sclerosis also predicted adverse events.
Flynn et al., analyzed 1150 patients undergoing isolated
CABG, 483 patients were excluded due to absence of
echocardiographic study 30 days before surgery. Of the 627
suitable patients for enrollment in the study, 33% had signif-
icant aortic sclerosis, a ﬁnding which was associated with
higher morbidity and mortality in short term and long term
follow-up periods.15
The association between AVS and cardiovascular risk fac-
tors may be explained by the fact that both conditions share
some similar pathophysiological mechanisms. The early lesions
of aortic sclerosis showed accumulation of apolipoprotien
(apo) B, apo (E), macrophage and a–actin expressing cells16
with evidence of LDL oxidation.17 There is evidence of inﬂam-
matory cell inﬁltrate with macrophages and T-lymphocytes. A
subset of macrophages produce proteins such as osteopontin
that mediate tissue calciﬁcation.18–20 In addition to its patho-
physiological link to atherosclerosis, aortic valve sclerosis
may be associated with adverse cardiovascular outcomes.
The mechanism of the association between AVS and adverse
events is not caused by the valve lesion itself as the valve hemo-
dynamics are not altered.21
It has been proposed that AVS may be a marker for under-
lying disease process like inﬂammation and endothelial dys-
function that are involved in the adverse events associated
with AVS.22,23
Some studies showed that AVS is associated with markers
of systemic inﬂammation like C-reactive protein, ﬁbrinogen
and homocystein.24–27
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between AVS and adverse outcome is the association between
AVS and systemic endothelial dysfunction as evidenced by
decreased brachial ﬂow- mediated dilatation in patients with
AVS.21
5. Limitations of the study
Relatively small sample size. Also, the study did not include
laboratory markers like markers of systemic inﬂammation or
studies for evaluation of endothelial function which could pro-
vide a possible pathophysiologic mechanism for the develop-
ment of adverse events.
6. Conclusion
The present study suggests that AVS is associated with MACE
after elective PCI using BMS. Further studies are required to
ascertain the pathophysiologic link between AVS and the
development of adverse events which could lead to a possible
therapeutic intervention to reduce the rate of adverse events.
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